ImmunoPrecise Antibodies Unveils Breakthrough LENSai™ Technology for Early Detection of Anti-Drug-Antibody Risk

Reuters

Jul 24, 2025

ImmunoPrecise Antibodies Unveils Breakthrough LENSai™ Technology for Early Detection of Anti-Drug-Antibody Risk

ImmunoPrecise Antibodies Ltd. has announced new findings from an expanded study demonstrating the effectiveness of its LENSai™ Immunogenicity Screening in predicting Anti-Drug-Antibody $(ADA.AU)$ risk for therapeutic proteins before clinical trials. The study analyzed 217 marketed and clinical-stage antibodies, making it the largest public ADA dataset to predict immunogenicity risk. LENSai™ offers a significant advantage by enabling rapid candidate triage using a single composite score system that accurately flags high-risk candidates. The proprietary HYFT-powered engine evaluates nearly 900 HLA variants and performs a whole-proteome humanness scan, providing detailed immunogenicity scanning. These results have already been presented, showcasing the platform's ability to potentially shorten pre-clinical cycles and reduce costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250724002460) on July 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2553818788"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553818788\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553818788?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553818788","market":"us","top_or_hot":-1,"title":"ImmunoPrecise Antibodies Unveils Breakthrough LENSai™ Technology for Early Detection of Anti-Drug-Antibody Risk","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Unveils Breakthrough LENSai™ Technology for Early Detection of Anti-Drug-Antibody Risk\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. has announced new findings from an expanded study demonstrating the effectiveness of its LENSai™ Immunogenicity Screening in predicting Anti-Drug-Antibody <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> risk for therapeutic proteins before clinical trials. The study analyzed 217 marketed and clinical-stage antibodies, making it the largest public ADA dataset to predict immunogenicity risk. LENSai™ offers a significant advantage by enabling rapid candidate triage using a single composite score system that accurately flags high-risk candidates. The proprietary HYFT-powered engine evaluates nearly 900 HLA variants and performs a whole-proteome humanness scan, providing detailed immunogenicity scanning. These results have already been presented, showcasing the platform's ability to potentially shorten pre-clinical cycles and reduce costs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250724002460) on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoPrecise Antibodies Unveils Breakthrough LENSai™ Technology for Early Detection of Anti-Drug-Antibody Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoPrecise Antibodies Unveils Breakthrough LENSai™ Technology for Early Detection of Anti-Drug-Antibody Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-24 20:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmunoPrecise Antibodies Unveils Breakthrough LENSai™ Technology for Early Detection of Anti-Drug-Antibody Risk\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmunoPrecise Antibodies Ltd. has announced new findings from an expanded study demonstrating the effectiveness of its LENSai™ Immunogenicity Screening in predicting Anti-Drug-Antibody <a href=\"https://laohu8.com/S/ADA.AU\">$(ADA.AU)$</a> risk for therapeutic proteins before clinical trials. The study analyzed 217 marketed and clinical-stage antibodies, making it the largest public ADA dataset to predict immunogenicity risk. LENSai™ offers a significant advantage by enabling rapid candidate triage using a single composite score system that accurately flags high-risk candidates. The proprietary HYFT-powered engine evaluates nearly 900 HLA variants and performs a whole-proteome humanness scan, providing detailed immunogenicity scanning. These results have already been presented, showcasing the platform's ability to potentially shorten pre-clinical cycles and reduce costs.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250724002460) on July 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nNDLKmN3S:1","article_id":"2553818788","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553818788","pubTimestamp":1753359748,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmunoPrecise Antibodies Ltd. has announced new findings from an expanded study demonstrating the effectiveness of its LENSai Immunogenicity Screening in predicting Anti-Drug-Antibody  risk for therapeutic proteins before clinical trials. The study analyzed 217 marketed and clinical-stage antibodies, making it the largest public ADA dataset to predict immunogenicity risk. LENSai offers a significant advantage by enabling rapid candidate triage using a single composite score system that accurately flags high-risk candidates. The proprietary HYFT-powered engine evaluates nearly 900 HLA variants and performs a whole-proteome humanness scan, providing detailed immunogenicity scanning. These results have already been presented, showcasing the platform's ability to potentially shorten pre-clinical cycles and reduce costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务"},"translate_title":"ImmunoPrecise Antibodies推出突破性LENSai™抗药抗体风险早期检测技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":0.9},"content_text":"ImmunoPrecise Antibodies Unveils Breakthrough LENSai™ Technology for Early Detection of Anti-Drug-Antibody Risk\n    \n\n        ImmunoPrecise Antibodies Ltd. has announced new findings from an expanded study demonstrating the effectiveness of its LENSai™ Immunogenicity Screening in predicting Anti-Drug-Antibody $(ADA.AU)$ risk for therapeutic proteins before clinical trials. The study analyzed 217 marketed and clinical-stage antibodies, making it the largest public ADA dataset to predict immunogenicity risk. LENSai™ offers a significant advantage by enabling rapid candidate triage using a single composite score system that accurately flags high-risk candidates. The proprietary HYFT-powered engine evaluates nearly 900 HLA variants and performs a whole-proteome humanness scan, providing detailed immunogenicity scanning. These results have already been presented, showcasing the platform's ability to potentially shorten pre-clinical cycles and reduce costs.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmunoPrecise Antibodies Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250724002460) on July 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}